News

Cancer Research15d
Clinicopathologic Features, Molecular Landscape, and Prognostic Implications of Ovarian Low-grade Serous Tumors with Histologic Transformation
1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. *Corresponding Author: M.H. Chui, Department of Pathology and Laboratory Medicine, ...
The Lancet21d
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial
Copyright: © 2025 The Author(s). Published by Elsevier Ltd.
The Lancet24d
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial
Among patients with previously untreated advanced hepatocellular carcinoma, toripalimab plus bevacizumab resulted ... This randomised, open-label, multicentre, active control, phase 3 study was ...
Frontiers26d
Comprehensive analyses of telomerase component DKC1 and its association with clinical, molecular and immune landscapes in uterine corpus endometrial carcinoma
Telomerase activation is essential to malignant transformation and progression including uterine corpus endometrial carcinoma (UCEC), while telomerase co-factor DKC1-mediated RNA pseudouridylation is ...
SciELO28d
ESR1 overexpression is a biomarker of relapse and worse prognosis in stage I endometrioid endometrial carcinoma
Type I, or endometrioid endometrial carcinoma (EEC), is the most frequent subtype and often shows a good prognosis. In contrast, type II tumors, or non-endometrioid carcinomas, represent the minority ...
Frontiers29d
Unveiling drug resistance pathways in high-grade serous ovarian cancer(HGSOC): recent advances and future perspectives
High-Grade Serous Ovarian Carcinoma (HGSOC) represents the most prevalent and lethal subtype of ovarian cancer, with approximately 225,000 new cases reported globally each year and a five-year ...